Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 3/2019

27.04.2019 | Original Article

In vitro evaluation of FL118 and 9-Q20 cytotoxicity and cellular uptake in 2D and 3D different cell models

verfasst von: Qi Weng, Leilei Zhou, Lihua Xia, Yixin Zheng, Xiangli Zhang, Fengzhi Li, Qingyong Li

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Recent researches are attempting to verify that the 3D cell models can provide a gap bridge between in vitro and in vivo for anticancer drug evaluations. The aim of this study was to continue the development of novel in vitro 3D cell models and the investigation of the cellular uptake mechanism of camptothecin (CPT) and its derivatives [FL118 (10,11-methylenedioxy-20(S)-camptothecin), 9-Q20 (9-p-trifluoromethylphenyl-10,11-methylenedioxy-20(S)-camptothecin)] in 2D and 3D cell models.

Methods

The 3D cell models were established using ultralow attachment 96-well plates. The cytotoxicity of CPT, FL118, and 9-Q20 was evaluated by MTT method. The effects of compound concentration, incubation time, temperature, and transporter inhibitors on the cellular uptake of CPT, FL118, and 9-Q20 were examined in 2D and 3D cell models.

Results

The cytotoxicity of CPT, FL118, and 9-Q20 was lower in 3D cell models than 2D cell models. In 2D Caco-2 cell model, the uptake rate of CPT, FL118, and 9-Q20 was faster during the early time of incubation. In 3D Caco-2 cell model, the uptake capacity of CPT, FL118, and 9-Q20 was significantly improved over time. In 3D Caco-2 cell model, Verapamil (P-gp inhibitor) and Gefitinib (BCRP inhibitor) more significantly increased the uptake of CPT and 9-Q20. In contrast, P-gp and BCRP did not affect the accumulation of FL118 in 2D and 3D Caco-2 cell models. The accumulation of CPT, FL118, and 9-Q20 was greater in HepG2 cells than HCT116 cells.

Conclusion

The 3D cell models provided more potency information on the process of cellular uptake of CPT, FL118, and 9-Q20, which more objectively reflected the drug sensitivity and drug resistance in vivo compared with the 2D cell models.
Literatur
2.
Zurück zum Zitat Huimin L, Ming H (2005) Absorption and metabolism of genistein and its five isoflavone analogs in the human intestinal Caco-2 model. Cancer Chemother Pharmacol 55(2):159–169CrossRef Huimin L, Ming H (2005) Absorption and metabolism of genistein and its five isoflavone analogs in the human intestinal Caco-2 model. Cancer Chemother Pharmacol 55(2):159–169CrossRef
3.
Zurück zum Zitat Chantal B, JérMe G, Michel D, Chantal F, Dominique B, Richard B (2005) Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin. Cancer Chemother Pharmacol 56(2):173–181CrossRef Chantal B, JérMe G, Michel D, Chantal F, Dominique B, Richard B (2005) Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin. Cancer Chemother Pharmacol 56(2):173–181CrossRef
4.
Zurück zum Zitat Ya C, Depinho RA, Matthias E, Karen V (2011) Cancer research: past, present and future. Nat Rev Cancer 11(10):749–754CrossRef Ya C, Depinho RA, Matthias E, Karen V (2011) Cancer research: past, present and future. Nat Rev Cancer 11(10):749–754CrossRef
5.
Zurück zum Zitat Shin CS, Kwak B, Han B, Park K (2013) Development of an in vitro 3D tumor model to study therapeutic efficiency of an anticancer drug. Mol Pharm 10(6):2167–2175PubMedCrossRef Shin CS, Kwak B, Han B, Park K (2013) Development of an in vitro 3D tumor model to study therapeutic efficiency of an anticancer drug. Mol Pharm 10(6):2167–2175PubMedCrossRef
6.
Zurück zum Zitat Watanabe T, Hasegawa T, Takahashi H, Ishibashi T, Itagaki H, Sugibayashi K (2002) Utility of MTT assay in three-dimensional cultured human skin model as an alternative for draize skin irritation test: approach using diffusion law of irritant in skin and toxicokinetics–toxicodynamics correlation. Pharm Res 19(5):669–675PubMedCrossRef Watanabe T, Hasegawa T, Takahashi H, Ishibashi T, Itagaki H, Sugibayashi K (2002) Utility of MTT assay in three-dimensional cultured human skin model as an alternative for draize skin irritation test: approach using diffusion law of irritant in skin and toxicokinetics–toxicodynamics correlation. Pharm Res 19(5):669–675PubMedCrossRef
7.
Zurück zum Zitat Jong Bin K (2005) Three-dimensional tissue culture models in cancer biology. Semin Cancer Biol 15(5):365–377CrossRef Jong Bin K (2005) Three-dimensional tissue culture models in cancer biology. Semin Cancer Biol 15(5):365–377CrossRef
8.
Zurück zum Zitat Krause S, Maffini MV, Soto AM, Sonnenschein C (2010) The microenvironment determines the breast cancer cells’ phenotype: organization of MCF7 cells in 3D cultures. BMC Cancer 10(1):263–263PubMedPubMedCentralCrossRef Krause S, Maffini MV, Soto AM, Sonnenschein C (2010) The microenvironment determines the breast cancer cells’ phenotype: organization of MCF7 cells in 3D cultures. BMC Cancer 10(1):263–263PubMedPubMedCentralCrossRef
9.
Zurück zum Zitat Chandraiah G, Mandip S (2016) AlgiMatrix?-based 3D cell culture system as an in vitro tumor model: an important tool in cancer research. Methods Mol Biol 1379:117–128CrossRef Chandraiah G, Mandip S (2016) AlgiMatrix?-based 3D cell culture system as an in vitro tumor model: an important tool in cancer research. Methods Mol Biol 1379:117–128CrossRef
12.
Zurück zum Zitat Chitcholtan Kenny, Sykes Peter H, Asselin Eric, Sophie Evans (2013) Differences in growth properties of endometrial cancer in three; dimensional (3D) culture and 2D cell monolayer. Exp Cell Res 319(1):75–87PubMedCrossRef Chitcholtan Kenny, Sykes Peter H, Asselin Eric, Sophie Evans (2013) Differences in growth properties of endometrial cancer in three; dimensional (3D) culture and 2D cell monolayer. Exp Cell Res 319(1):75–87PubMedCrossRef
14.
Zurück zum Zitat Gottlieb JA, Guarino AM, Call JB, Oliverio VT, Block JB (1970) Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 54(6):461–470PubMed Gottlieb JA, Guarino AM, Call JB, Oliverio VT, Block JB (1970) Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 54(6):461–470PubMed
15.
Zurück zum Zitat Marzi L, Agama K, Murai J, Difilippantonio S, James A, Peer CJ, Figg WD, Beck D, Msa E, Cushman M (2018) Novel fluoroindenoisoquinoline non-camptothecin topoisomerase I inhibitors. Mol Cancer Ther 17(8):1694–1704PubMedPubMedCentralCrossRef Marzi L, Agama K, Murai J, Difilippantonio S, James A, Peer CJ, Figg WD, Beck D, Msa E, Cushman M (2018) Novel fluoroindenoisoquinoline non-camptothecin topoisomerase I inhibitors. Mol Cancer Ther 17(8):1694–1704PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Lorusso D, Pietragalla A, Mainenti S, Masciullo V, Di VG, Scambia G (2010) Review role of topotecan in gynaecological cancers: current indications and perspectives. Crit Rev Oncol Hematol 74(3):163–174PubMedCrossRef Lorusso D, Pietragalla A, Mainenti S, Masciullo V, Di VG, Scambia G (2010) Review role of topotecan in gynaecological cancers: current indications and perspectives. Crit Rev Oncol Hematol 74(3):163–174PubMedCrossRef
18.
Zurück zum Zitat Biren S, Murugesan G, Jayeeta D, Ahamed S, Celeste C, Luz Z, Ahamed N, Mecide G, Dale S, Yong L (2008) Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia. Anticancer Drugs 19(4):411–420CrossRef Biren S, Murugesan G, Jayeeta D, Ahamed S, Celeste C, Luz Z, Ahamed N, Mecide G, Dale S, Yong L (2008) Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia. Anticancer Drugs 19(4):411–420CrossRef
19.
Zurück zum Zitat Xiang L, Cao S, Cheng Q, Keefe JT, Rustum YM, Li F (2012) A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity. PloS One 7(9):e45571CrossRef Xiang L, Cao S, Cheng Q, Keefe JT, Rustum YM, Li F (2012) A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity. PloS One 7(9):e45571CrossRef
20.
Zurück zum Zitat Li F, Ling X, Harris DL, Liao J, Wang Y, Westover D, Jiang G, Xu B, Boland PM, Jin C (2017) Topoisomerase I (Top1): a major target of FL118 for its antitumor efficacy or mainly involved in its side effects of hematopoietic toxicity? Am J Cancer Res 7(2):370–382PubMedPubMedCentral Li F, Ling X, Harris DL, Liao J, Wang Y, Westover D, Jiang G, Xu B, Boland PM, Jin C (2017) Topoisomerase I (Top1): a major target of FL118 for its antitumor efficacy or mainly involved in its side effects of hematopoietic toxicity? Am J Cancer Res 7(2):370–382PubMedPubMedCentral
21.
Zurück zum Zitat Xiang L, Xiaojun L, Kai Z, Nicholas S, Joshua P, Fengzhi L (2015) FL118, a novel camptothecin analogue, overcomes irinotecan and topotecan resistance in human tumor xenograft models. Am J Transl Res 7(10):1765–1781 Xiang L, Xiaojun L, Kai Z, Nicholas S, Joshua P, Fengzhi L (2015) FL118, a novel camptothecin analogue, overcomes irinotecan and topotecan resistance in human tumor xenograft models. Am J Transl Res 7(10):1765–1781
23.
Zurück zum Zitat Ling X, Li F (2013) An intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI). Am J Transl Res 5(2):139PubMedPubMedCentral Ling X, Li F (2013) An intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI). Am J Transl Res 5(2):139PubMedPubMedCentral
24.
Zurück zum Zitat Zhen Z, Shen ZL, Zhai S, Xu JL, Hui L, Qin S, Li QY (2017) Transport of curcumin derivatives in Caco-2 cell monolayers. Eur J Pharm Biopharm 117:123–131CrossRef Zhen Z, Shen ZL, Zhai S, Xu JL, Hui L, Qin S, Li QY (2017) Transport of curcumin derivatives in Caco-2 cell monolayers. Eur J Pharm Biopharm 117:123–131CrossRef
25.
Zurück zum Zitat Piccinini F, Tesei A, Arienti C, Bevilacqua A (2017) Cell counting and viability assessment of 2D and 3D Cell cultures: expected reliability of the Trypan Blue assay. Biol Proced Online 19(1):8PubMedPubMedCentralCrossRef Piccinini F, Tesei A, Arienti C, Bevilacqua A (2017) Cell counting and viability assessment of 2D and 3D Cell cultures: expected reliability of the Trypan Blue assay. Biol Proced Online 19(1):8PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat Curran S, Achilli TM, Leary E, Wilks BT, Vantangoli MM, Boekelheide K, Morgan JR (2015) A 3D spheroid system to evaluate inhibitors of the ABCG2 transporter in drug uptake and penetration. Technology 3(01):54–63CrossRef Curran S, Achilli TM, Leary E, Wilks BT, Vantangoli MM, Boekelheide K, Morgan JR (2015) A 3D spheroid system to evaluate inhibitors of the ABCG2 transporter in drug uptake and penetration. Technology 3(01):54–63CrossRef
27.
Zurück zum Zitat Liang QQ, Li YS (2013) A rapid and accurate method for determining protein content in dairy products based on asynchronous-injection alternating merging zone flow-injection spectrophotometry. Food Chem 141(3):2479–2485PubMedCrossRef Liang QQ, Li YS (2013) A rapid and accurate method for determining protein content in dairy products based on asynchronous-injection alternating merging zone flow-injection spectrophotometry. Food Chem 141(3):2479–2485PubMedCrossRef
28.
Zurück zum Zitat Franziska H, Heike M, Claudia D, Jonathan W, Wolfgang MK, Kunz-Schughart LA (2010) Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol 148(1):3–15CrossRef Franziska H, Heike M, Claudia D, Jonathan W, Wolfgang MK, Kunz-Schughart LA (2010) Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol 148(1):3–15CrossRef
29.
Zurück zum Zitat JérMe A, Jean-Marie T, Marine GG, Jean-Marie G, Didier R, Daniel A, Jean-Louis M, FranOis G (2002) Combination of topotecan and oxaliplatin in inoperable hepatocellular cancer patients. Am J Clin Oncol 25(2):198CrossRef JérMe A, Jean-Marie T, Marine GG, Jean-Marie G, Didier R, Daniel A, Jean-Louis M, FranOis G (2002) Combination of topotecan and oxaliplatin in inoperable hepatocellular cancer patients. Am J Clin Oncol 25(2):198CrossRef
30.
Zurück zum Zitat Tomoo S, Jun-Ichi T, Toshitaka F, Koji F, Koji K, Shuji M, Satoshi M, Akihiko G, Narikazu B (2013) risk factors for severe adverse effects and treatment-related deaths in japanese patients treated with irinotecan-based chemotherapy: a postmarketing survey. Jpn J Clin Oncol 43(5):483–491CrossRef Tomoo S, Jun-Ichi T, Toshitaka F, Koji F, Koji K, Shuji M, Satoshi M, Akihiko G, Narikazu B (2013) risk factors for severe adverse effects and treatment-related deaths in japanese patients treated with irinotecan-based chemotherapy: a postmarketing survey. Jpn J Clin Oncol 43(5):483–491CrossRef
31.
Zurück zum Zitat Karlssona H, Larsson R, Nygren P (2012) Loss of cancer drug activity in colon cancer HCT-116 cells during spheroid formation in a new 3-D spheroid cell culture system. Exp Cell Res 318(13):1577–1585CrossRef Karlssona H, Larsson R, Nygren P (2012) Loss of cancer drug activity in colon cancer HCT-116 cells during spheroid formation in a new 3-D spheroid cell culture system. Exp Cell Res 318(13):1577–1585CrossRef
32.
Zurück zum Zitat Breslin S, O’Driscoll L (2013) Three-dimensional cell culture: the missing link in drug discovery. Drug Discov Today 18(5–6):240–249PubMedCrossRef Breslin S, O’Driscoll L (2013) Three-dimensional cell culture: the missing link in drug discovery. Drug Discov Today 18(5–6):240–249PubMedCrossRef
33.
Zurück zum Zitat Achilli TM, Mccalla S, Meyer J, Tripathi A, Morgan JR (2014) Multilayer spheroids to quantify drug uptake and diffusion in 3D. Mol Pharm 11(7):2071–2081PubMedPubMedCentralCrossRef Achilli TM, Mccalla S, Meyer J, Tripathi A, Morgan JR (2014) Multilayer spheroids to quantify drug uptake and diffusion in 3D. Mol Pharm 11(7):2071–2081PubMedPubMedCentralCrossRef
35.
Zurück zum Zitat Elliott NT, Yuan F (2015) A review of three-dimensional in vitro tissue models for drug discovery and transport studies. J Pharm Sci 100(1):59–74CrossRef Elliott NT, Yuan F (2015) A review of three-dimensional in vitro tissue models for drug discovery and transport studies. J Pharm Sci 100(1):59–74CrossRef
36.
Zurück zum Zitat Szakács G, Váradi A, Özvegy-Laczka C, Sarkadi B (2008) The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME–Tox). Drug Discov Today 13(9):379–393PubMedCrossRef Szakács G, Váradi A, Özvegy-Laczka C, Sarkadi B (2008) The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME–Tox). Drug Discov Today 13(9):379–393PubMedCrossRef
37.
Zurück zum Zitat Huang SM (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9(3):215–236PubMedCrossRef Huang SM (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9(3):215–236PubMedCrossRef
38.
Zurück zum Zitat Sun FF, Hu YH, Xiong LP, Tu XY, Zhao JH, Chen SS, Song J, Ye XQ (2015) Enhanced expression of stem cell markers and drug resistance in sphere-forming non-small cell lung cancer cells. Int J Clin Exp Pathol 8(6):6287PubMedPubMedCentral Sun FF, Hu YH, Xiong LP, Tu XY, Zhao JH, Chen SS, Song J, Ye XQ (2015) Enhanced expression of stem cell markers and drug resistance in sphere-forming non-small cell lung cancer cells. Int J Clin Exp Pathol 8(6):6287PubMedPubMedCentral
39.
Zurück zum Zitat Hans G, Ramon S, Jaap V, George P, Jonge MJA, De Martin D, Christel VH, Francis S, Rosendo O, Joan PO (2003) Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors. Clin Cancer Res 9(11):4101–4107 Hans G, Ramon S, Jaap V, George P, Jonge MJA, De Martin D, Christel VH, Francis S, Rosendo O, Joan PO (2003) Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors. Clin Cancer Res 9(11):4101–4107
40.
Zurück zum Zitat Graziella P, Beretta GL, Franco Z (2004) Gimatecan, a novel camptothecin with a promising preclinical profile. Anticancer Drugs 15(6):545CrossRef Graziella P, Beretta GL, Franco Z (2004) Gimatecan, a novel camptothecin with a promising preclinical profile. Anticancer Drugs 15(6):545CrossRef
41.
Zurück zum Zitat Min H, Heyong G, Yi C, Hong Z, Yujun C, Xiongwen Z, Zehong M, Hualiang J, Jian Z, Hongwu S (2007) Chimmitecan, a novel 9-substituted camptothecin, with improved anticancer pharmacologic profiles in vitro and in vivo. Clin Cancer Res 13(4):1298–1307CrossRef Min H, Heyong G, Yi C, Hong Z, Yujun C, Xiongwen Z, Zehong M, Hualiang J, Jian Z, Hongwu S (2007) Chimmitecan, a novel 9-substituted camptothecin, with improved anticancer pharmacologic profiles in vitro and in vivo. Clin Cancer Res 13(4):1298–1307CrossRef
42.
Zurück zum Zitat Rodríguez-Berna G, Mangas-Sanjuán V, Gonzalez-Alvarez M, Gonzalez-Alvarez I, García-Giménez JL, Cabañas MJD, Bermejo M, Corma A (2014) A promising camptothecin derivative: semisynthesis, antitumor activity and intestinal permeability. Eur J Med Chem 83(16):366–373PubMedCrossRef Rodríguez-Berna G, Mangas-Sanjuán V, Gonzalez-Alvarez M, Gonzalez-Alvarez I, García-Giménez JL, Cabañas MJD, Bermejo M, Corma A (2014) A promising camptothecin derivative: semisynthesis, antitumor activity and intestinal permeability. Eur J Med Chem 83(16):366–373PubMedCrossRef
43.
Zurück zum Zitat Smalley K, Lioni M, Herlyn M (2006) Life isn’t flat: taking cancer biology to the next dimension. Vitro Cell Dev Biol Anim 42(8/9):242–247CrossRef Smalley K, Lioni M, Herlyn M (2006) Life isn’t flat: taking cancer biology to the next dimension. Vitro Cell Dev Biol Anim 42(8/9):242–247CrossRef
Metadaten
Titel
In vitro evaluation of FL118 and 9-Q20 cytotoxicity and cellular uptake in 2D and 3D different cell models
verfasst von
Qi Weng
Leilei Zhou
Lihua Xia
Yixin Zheng
Xiangli Zhang
Fengzhi Li
Qingyong Li
Publikationsdatum
27.04.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 3/2019
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-019-03846-x

Weitere Artikel der Ausgabe 3/2019

Cancer Chemotherapy and Pharmacology 3/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.